Evaluating wait times from screening to breast cancer diagnosis among women undergoing organised assessment *vs* usual care

Anna M Chiarelli*,[1,2], Derek Muradali[1,3,4], Kristina M Blackmore[1], Courtney R Smith[1], Lucia Mirea[5], Vicky Majpruz[1], Frances P O'Malley[6], May Lynn Quan[7,8] and Claire MB Holloway[9,10]

Background: Timely coordinated diagnostic assessment following an abnormal screening mammogram reduces patient anxiety and may optimise breast cancer prognosis. Since 1998, the Ontario Breast Screening Program (OBSP) has offered organised assessment through Breast Assessment Centres (BACs). For OBSP women seen at a BAC, an abnormal mammogram is followed by coordinated referrals through the use of navigators for further imaging, biopsy, and surgical consultation as indicated. For OBSP women seen through usual care (UC), further diagnostic imaging is arranged directly from the screening centre and/or through their physician; results must be communicated to the physician who is then responsible for arranging any necessary biopsy and/or surgical consultation. This study aims to evaluate factors associated with diagnostic wait times for women undergoing assessment through BAC and UC.

Methods: Of the 2 147 257 women aged 50–69 years screened in the OBSP between 1 January 2002 and 31 December 2009, 155 866 (7.3%) had an abnormal mammogram. A retrospective design identified two concurrent cohorts of women diagnosed with screen-detected breast cancer at a BAC ($n = 4217$; 47%) and UC ($n = 4827$; 53%). Multivariable logistic regression analyses examined associations between wait times and assessment and prognostic characteristics by pathway. A two-sided 5% significance level was used.

Results: Screened women with breast cancer were two times more likely to be diagnosed within 7 weeks when assessed through a BAC *vs* UC (OR = 1.91, 95% CI = 1.73–2.10). In addition, compared with UC, women assessed through a BAC were significantly more likely to have their first assessment procedure within 3 weeks of their abnormal mammogram (OR = 1.25, 95% CI = 1.12–1.39), ⩽3 assessment procedures (OR = 1.54, 95% CI = 1.41–1.69), ⩽2 assessment visits (OR = 1.86, 95% CI = 1.70–2.05), and ⩾2 procedures per visit (OR = 1.41, 95% CI = 1.28–1.55). Women diagnosed through a BAC were also more likely than those in UC to have imaging (OR = 1.99, 95% CI = 1.44–2.75) or a biopsy (OR = 3.69, 95% CI = 2.64–5.15) *vs* consultation only at their first assessment visit, and two times more likely to have a core or FNA biopsy than a surgical biopsy (OR = 2.08, 95% CI = 1.81–2.40). Having ⩽2 assessment visits was more likely to reduce time to diagnosis for women assessed through a BAC compared with UC (BAC OR = 10.58, 95% CI = 8.96–12.50; UC OR = 4.47, 95% CI = 3.94–5.07), as was having ⩽3 assessment procedures (BAC OR = 4.97, 95% CI = 4.26–5.79; UC OR = 2.95, 95% CI = 2.61–3.33). Income quintile affected wait times only in women diagnosed in UC, with those in the two highest quintiles more likely to receive a diagnosis in 7 weeks.

Conclusions: Women with screen-detected breast cancer in OBSP were more likely to have shorter wait times if they were diagnosed through organised assessment. This might be as a result of women diagnosed through a BAC having more procedures per visit, procedures scheduled in shorter intervals, and imaging or biopsy on their first visit. Given the significant improvement in timeliness to diagnosis, women with abnormal mammograms should be managed through organised assessment.

To ensure the benefits of early detection by mammography (The Canadian Task Force on Preventive Health Care, 2011; Nelson et al, 2016) women with abnormal screening results must have access to timely and accurate diagnostic assessment. One of the essential components of screening centres is appropriate follow-up of women with abnormal findings with an effective referral system (The Workshop Group, 1989). The time required for assessment of an abnormal mammogram is associated with patient stress and anxiety (Sutton et al, 1995; Rimer and Bluman, 1997; Brett et al, 1998) and delays in diagnostic times have a negative impact on the prognosis of screen-detected breast cancers (Olivotto et al, 2002; Ganry et al, 2004).

A study of Canadian screening programs found that age at screen, family history of breast cancer, and screening history were not associated with delays in breast cancer diagnosis (Olivotto et al, 2002). However, this study as well as several others found that diagnostic intervals actually decreased for screened women with high-suspicion mammograms (Caplan et al, 2000; Olivotto et al, 2002; Ganry et al, 2004; Bairati et al, 2007; Borugian et al, 2008). Shorter diagnostic times were also seen for women with higher income (Bairati et al, 2007), larger tumour size (Bairati et al, 2007), more advanced stage (Jiang et al, 2015), and for women who attended screening programs that used core biopsies more often than open biopsies (Olivotto et al, 2001a).

The Ontario Breast Assessment Collaborative Group was established in 1998 to guide development of coordinated multidisciplinary approaches for facilities to provide organised breast assessment (Ontario Breast Screening Program, 2001). Within the Ontario Breast Screening Program (OBSP), facilities that qualify as a Breast Assessment Centre (BAC) have a patient navigation system that coordinates referrals through a defined pathway and have access to diagnostic imaging, image-guided biopsies, pathology, and surgical services. Canadian breast screening programs have reported shorter diagnostic intervals for women who had coordinated referrals from screening centres to diagnostic facilities (Olivotto et al, 2001b; Decker et al, 2004; Psooy et al, 2004; Borugian et al, 2008; Baliski et al, 2014). For women screened in the OBSP, a previous study showed that women receiving work-up through organised assessment had shorter diagnostic wait times with a biopsy than for those evaluated through usual care (UC) (Quan et al, 2012). However, this study only utilised 1 year of data, and did not explore the effect of various assessment and prognostic characteristics on diagnostic intervals. A more recent Ontario study of screened women had similar findings; however, a large proportion (20.5%) underwent opportunistic screening and only invasive cancers were included (Jiang et al, 2015).

After 15 years of implementation of BACs in the OBSP, this study aims to evaluate the effectiveness of organised breast assessment. Wait times from an abnormal mammogram to breast cancer diagnosis will be compared between concurrent cohorts of women aged 50–69 years screened in the OBSP undergoing assessment through BAC and UC. The association of assessment and prognostic characteristics with wait times will be examined separately in BAC and UC cohorts.

MATERIALS AND METHODS

Study population. The OBSP has operated since 1990 to deliver a population-based breast screening program to eligible women (Chiarelli et al, 2013). Women are not eligible if they have had a prior history of breast cancer, an augmentation mammoplasty, or if they currently have acute breast symptoms. This study identified women aged 50–69 years screened through the OBSP with an abnormal mammogram between 1 January 2002 and 31 December 2009. Mammography consisted of standard craniocaudal and mediolateral oblique views performed by certified mammography technologists on equipment that meets or exceeds that specified by Canadian Association of Radiologists' Mammography Accreditation Program (CAR-MAP). Of those with an abnormal mammogram, one cohort underwent diagnostic assessment through a BAC and the other through UC. Although all women in the study were screened at an OBSP centre, referral to a BAC was dependent on whether the screening centre was affiliated with a BAC. Women were then followed prospectively to determine whether there was a breast cancer diagnosis within a year of the abnormal screening mammogram. During the time period of this study, women were screened at 150 OBSP centres and assessed at 35 BACs. The study was approved by the University of Toronto Research Ethics Board and informed consent was not required.

Ontario facilities that provide organised assessment must meet established criteria in order to qualify as a BAC. Criteria include: having certified mammography technologists and equipment that meets or exceeds that specified by CAR-MAP; providing all abnormal mammographic work-up including special mammographic views and image-guided core biopsy; providing radiological, surgical, and pathologic consultation with experts in breast evaluation; and providing a navigator for patient support and coordination of referrals. The BACs may either perform all the required services for abnormal mammographic work-up or establish networks with facilities to provide the services (Quan et al, 2012). For OBSP women seen through UC, further diagnostic imaging after an abnormal mammogram is arranged directly from the screening centre and/or through their physician; results must be communicated to the physician who is then responsible for arranging any necessary biopsy and/or surgical consultation.

Selection of breast cancer cases. There were 2 147 257 women aged 50–69 years screened at an OBSP centre between 1 January 2002 and 31 December 2009. To allow for learning curves for new BACs, only women with an abnormal mammogram assessed after the first 6 months of operation were selected. All women diagnosed with unilateral, primary ductal carcinoma in situ (DCIS), or invasive breast cancer of any histological type were identified through record linkage with the Ontario Cancer Registry (OCR) (Jaro, 1995). Breast cancers detected within 12 months of the abnormal screening episode and classified as screen-detected by the program during follow-up were included. For these women, the last OBSP abnormal screening mammogram before diagnosis was included. Information for all women screened within the OBSP was obtained from data routinely collected by the Integrated Client Management System (ICMS) and OCR.

Demographics and breast cancer risk factors. Information on demographics and breast cancer risk factors comprises self-reported data in the ICMS, collected at the screening appointment. Age and year at screen were based on the date of abnormal mammogram before diagnosis. Women with a first-degree relative with breast or ovarian cancer or personal history of ovarian cancer were classified as having a positive family history. Menopausal status (premenopausal, postmenopausal), age at menarche ($\leqslant 11$ years, >11 years), and parity (nulliparous; first full-term pregnancy (FFTP) <30 years; FTTP $\geqslant 30$) were also measured. Women's postal code of residence at screening was linked to the 2006 Canadian Census (Wilkins, 1998) to determine socioeconomic status (SES) and community status. The SES was defined by five income quintiles (Q1 (low)–Q5 (high)). Community status included urban (population 10 000 +), rural ($<10 000$ and a strong metropolitan influenced zone (MIZ)), rural remote ($<10 000$ and a moderate MIZ), and rural very remote ($<10 000$ and a weak/no MIZ) (Statistics Canada, 1997).

Screening characteristics. Information on screening visit for each woman was obtained through the ICMS. An abnormal

Figure 1. Cohorts of women screened between 1 January 2002 and 31 December 2009 and diagnosed with breast cancer within the Ontario Breast Screening Program.

mammogram was defined as an initial screen for women who had only one OBSP mammogram, or a rescreen for women who had more than one mammogram. The type of mammography was recorded as screen film or digital. Mammographic density was recorded by the radiologist as <75% or ≥75%.

Assessment characteristics. Assessment procedures and dates were obtained through ICMS. Time (days) to a woman's first assessment procedure following an abnormal screening mammogram was calculated. Assessment procedures from abnormal screening mammogram to final diagnosis date included breast imaging (diagnostic mammogram, ultrasound, MRI), breast biopsy (fine-needle aspiration (FNA), core biopsy, open/surgical), and consultation (radiological, surgical, oncology, primary care). Procedures at first visit were categorised hierarchically as consultation only; imaging ± consultation (i.e., imaging only, imaging with consultation); and biopsy ± consultation or imaging (i.e., biopsy only; biopsy and consultation, biopsy and imaging, biopsy with imaging and consultation). First diagnostic assessment delay was defined as having a first assessment >3 weeks following an abnormal mammogram (Canadian Breast Cancer Screening Initiative Working Group, 2000). Number of assessment procedures, number of assessment visits, and average number of procedures per visit were calculated and categorised according to the median. Type of biopsy was defined as the woman's first biopsy procedure after abnormal mammogram and was either percutaneous (FNA, core biopsies) or surgical (open surgical, nodal/axillary, nodal/sentinel, or treatment surgery).

Diagnosis age refers to the age at screen-detected breast cancer diagnosis. Time (days) to breast cancer diagnosis was calculated from the date of the abnormal screening mammogram to the date of the first biopsy indicating malignancy. Diagnostic delay was defined as having a breast cancer diagnosis >7 weeks after an abnormal screening mammogram, a national timeliness target based on expert opinion and evidence review (Canadian Breast Cancer Screening Initiative Working Group, 2000; Canadian Partnership against Cancer, 2013).

Prognostic characteristics. Histological classification (invasive, DCIS) for breast cancers was obtained from the ICMS and OCR. Tumour morphology was coded using the International Classification of Diseases for Oncology (ICD-O), Second Edition, 1990 (World Health Organization, 1990). Data on tumour size (≤0.5; >0.5 to ≤1.0;

>1.0 to ≤2.0; >2.0), nodal status (positive, negative), and stage (I, II, III) were collected for invasive cases. The TNM classification scheme (American Joint Committee on Cancer, 2002) was used for staging of breast cancer. Tumour size was defined as the largest diameter of the invasive carcinoma. Lymph node status was defined by TNM criteria for women who had axillary assessment.

Statistical analysis. Risk factors and screening characteristics were compared between BAC and UC using multivariable logistic regression analyses, adjusted for age and/or year of screening. Similarly, the association of pathway (BAC/UC) with assessment and prognostic characteristics was examined using multivariable logistic regression to estimate adjusted odds ratios (ORs) and corresponding 95% confidence intervals (CIs) (Diggle et al, 2002). The association of risk, screening, assessment, and prognostic characteristics with delay in diagnosis (≤7 weeks vs >7 weeks) was examined separately for women assessed through BAC and UC to identify possible effect modification. Additional analyses examined stage and tumour size as quantitative exposure variables to assess trend effects. Wilcoxon rank-sum tests were used to test for differences in median time to diagnosis between pathways, overall and stratified by ≤3 and >3 procedures (Haynes, 2013). Finally, sensitivity analyses were performed on a subset of the cohort screened between 2006 and 2009 to examine whether differences between pathways persisted over time. All analyses were performed using SAS version 9.4 (SAS Institute Inc., 2008). Statistical tests were two sided and evaluated at a 5% significance level.

RESULTS

Of the 155 866 women with an abnormal mammogram, 9702 (6.2%) were diagnosed with breast cancer. Women were excluded if they resided outside Ontario (n = 29), had stage IV (n = 94), bilateral (n = 192) or non-primary (n = 333) breast cancer, or had a breast cancer diagnosis >1 year following an abnormal mammogram (n = 10). The final sample included 9044 (93.2%) eligible women, of whom 4217 (47%) were assessed through a BAC and 4827 (53%) through UC (Figure 1).

The mean age at screening was 59.7 years, with no significant differences in age group distribution between pathways (Table 1). Women evaluated in a BAC compared with UC were more likely to have their abnormal mammogram be a rescreen than an initial

Table 1. Adjusted ORs and 95% CIs for the association of risk factors and screening characteristics among women diagnosed with screen-detected breast cancers through a Breast Assessment Centre compared with Usual Care

Characteristics	Breast assessment type				
	Usual Care, $N = 4827$, n (%)	Breast Assessment Centre, $N = 4217$, n (%)	Overall, $N = 9044$, n (%)	Adjusted OR (95% CI)	P-value
Age at screening (years)[a]					
50–59	2335 (48.4)	2045 (48.5)	4380 (48.4)	1.00 (reference)	
60–69	2492 (51.6)	2172 (51.5)	4664 (51.6)	0.98 (0.90–1.06)	0.6170
Screen type[b]					
Initial	1859 (38.5)	1230 (29.2)	3089 (34.2)	1.00 (reference)	
Rescreen	2968 (61.5)	2987 (70.8)	5955 (65.8)	1.55 (1.41–1.70)	<0.0001
Period of screening[c]					
2002–2005	2060 (42.7)	1364 (32.3)	3424 (37.9)	1.00 (reference)	
2006–2009	2767 (57.3)	2853 (67.7)	5620 (62.1)	1.56 (1.43–1.70)	<0.0001
Mammography type[b]					
Screen film	4315 (89.4)	3325 (78.9)	7640 (84.5)	1.00 (reference)	
Digital	512 (10.6)	892 (21.1)	1404 (15.5)	1.89 (1.66–2.15)	<0.0001
Family history of breast or ovarian cancer[b]					
No	3799 (78.7)	3251 (77.1)	7050 (78.0)	1.00 (reference)	
Yes	1028 (21.3)	966 (22.9)	1994 (22.0)	1.09 (0.98–1.20)	0.1002
Menopausal status[b]					
Premenopausal	709 (14.7)	608 (14.4)	1317 (14.6)	1.00 (reference)	
Postmenopausal	4117 (85.3)	3609 (85.6)	7726 (85.4)	1.00 (0.88–1.14)	0.9949
Missing	1	0	1	–	
Age at menarche (years) [b]					
⩽11	874 (18.8)	814 (20.0)	1688 (19.3)	1.00 (reference)	
>11	3786 (81.2)	3261 (80.0)	7047 (80.7)	0.92 (0.82–1.02)	0.1170
Missing	167	142	309	–	
Parity[b]					
Nulliparous	70 (1.7)	91 (2.5)	161 (2.1)	1.00 (reference)	
Age at FFTP <30	3481 (83.5)	3056 (83.7)	6537 (83.6)	0.70 (0.51–0.96)	0.0270
Age at FFTP ⩾30	617 (14.8)	503 (13.8)	1120 (14.3)	0.63 (0.45–0.88)	0.0066
Missing	659	567	1226	–	
Mammographic density (%)[b]					
⩾75%	456 (9.4)	311 (7.4)	767 (8.5)	1.00 (reference)	
<75%	4371 (90.6)	3906 (92.6)	8277 (91.5)	1.34 (1.15–1.56)	0.0002
Community status[b]					
Urban	4117 (85.3)	3477 (82.5)	7594 (84.0)	1.00 (reference)	
Rural	297 (6.2)	214 (5.1)	511 (5.6)	0.87 (0.73–1.05)	0.1491
Rural remote	234 (4.8)	406 (9.6)	640 (7.1)	2.13 (1.80–2.52)	<0.0001
Rural very remote	177 (3.7)	119 (2.8)	296 (3.3)	0.80 (0.63–1.02)	0.0711
Missing	2	1	3		
Income quintile[b]					
1, Lowest	771 (16.1)	735 (17.5)	1506 (16.7)	1.00 (reference)	
2	912 (19.0)	842 (20.1)	1754 (19.5)	0.96 (0.84–1.10)	0.5626
3	934 (19.4)	804 (19.1)	1738 (19.3)	0.90 (0.78–1.03)	0.1216
4	988 (20.6)	848 (20.2)	1836 (20.4)	0.88 (0.77–1.01)	0.0691
5, Highest	1195 (24.9)	970 (23.1)	2165 (24.1)	0.85 (0.74–0.97)	0.0132
Missing	27	18	45	–	

Abbreviations: CI = confidence interval; FFTP = first full-term pregnancy; OR = odds ratio.
[a]Adjusted by year of screen.
[b]Adjusted by year of screen and age at screening.
[c]Adjusted by age at screening.

screen, have their abnormal mammogram after 2006 than before, and be assessed with digital rather than screen-film mammography. Family history of breast or ovarian cancer, menopausal status, and age at menarche did not differ between pathways. Women assessed through a BAC were less likely to be parous vs nulliparous regardless of age, and were significantly more likely to have less mammographically dense breasts (<75% vs ⩾75%) compared with UC. In addition, women assessed through a BAC were twice as likely to live in rural remote compared with urban regions, and less likely to be in the highest compared with lowest income quintile.

Compared with women assessed through UC, those assessed through a BAC were significantly more likely to have their first assessment procedure within 3 weeks of their abnormal mammogram (vs >3; OR = 1.25, 95% CI = 1.12–1.39), ⩽3 assessment procedures (vs >3; OR = 1.54, 95% CI = 1.41–1.69), ⩽2 assessment visits (vs >2; OR = 1.86, 95% CI = 1.70–2.05), and ⩾2 procedures per visit (vs <2; OR = 1.41, 95% CI = 1.28–1.55) (Table 2). In addition, women assessed through a BAC were more likely than those in UC to have imaging (OR = 1.99, 95% CI = 1.44–2.75) or a biopsy (OR = 3.69, 95% CI = 2.64–5.15) vs

Table 2. Adjusted ORs and 95% CIs for association of assessment and prognostic characteristics among women diagnosed with screen-detected breast cancers through a Breast Assessment Centre compared with Usual Care

Characteristics	Breast assessment type				
	Usual Care, $N = 4827$, n (%)	Breast Assessment Centre, $N = 4217$, n (%)	Overall, $N = 9044$, n (%)	Adjusted OR[a] (95% CI)	P-value
Time to first assessment procedure					
>3 Weeks	1056 (21.9)	794 (18.8)	1850 (20.5)	1.00 (reference)	
⩽3 Weeks	3771 (78.1)	3423 (81.2)	7194 (79.5)	1.25 (1.12–1.39)	<0.0001
Total assessment procedures					
>3 Procedures	2034 (42.1)	1336 (31.7)	3370 (37.3)	1.00 (reference)	
⩽3 Procedures	2793 (57.9)	2881 (68.3)	5674 (62.7)	1.54 (1.41–1.69)	<0.0001
Total assessment visits					
>2 Visits	1918 (39.7)	1089 (25.8)	3007 (33.2)	1.00 (reference)	
⩽2 Visits	2909 (60.3)	3128 (74.2)	6037 (66.8)	1.86 (1.70–2.05)	<0.0001
Procedures per visit (average)					
<2 Procedures per visit	3617 (74.9)	2895 (68.6)	6512 (72.0)	1.00 (reference)	
⩾2 Procedures per visit	1210 (25.1)	1322 (31.4)	2532 (28.0)	1.41 (1.28–1.55)	<0.0001
Procedure(s) at first visit					
Consultation only	148 (3.1)	54 (1.3)	202 (2.2)	1.00 (reference)	
Imaging (± consultation)	3944 (81.7)	3129 (74.2)	7073 (78.2)	1.99 (1.44–2.75)	<0.0001
Biopsy (± imaging or consultation)	735 (15.2)	1034 (24.5)	1769 (19.6)	3.69 (2.64–5.15)	<0.0001
First biopsy procedure (any visit)					
Open/surgical	787 (16.3)	346 (8.2)	1133 (12.5)	1.00 (reference)	
Core/FNA	4038 (83.7)	3870 (91.8)	7908 (87.5)	2.08 (1.81–2.40)	<0.0001
Missing	2	1	3	–	
Time to diagnosis					
>7 weeks	1776 (36.8)	1004 (23.8)	2780 (30.7)	1.00 (reference)	
⩽7 weeks	3051 (63.2)	3213 (76.2)	6264 (69.3)	1.91 (1.73–2.10)	<0.0001
Age at diagnosis (years)					
50–59	2299 (47.6)	2025 (48.0)	4324 (47.8)	1.00 (reference)	
60–70	2528 (52.4)	2192 (52.0)	4720 (52.2)	0.89 (0.75–1.05)	0.1552
Breast cancer classification					
DCIS	920 (19.1)	810 (19.2)	1730 (19.1)	1.00 (reference)	
Invasive	3907 (80.9)	3407 (80.8)	7314 (80.9)	1.00 (0.90–1.11)	0.9669
Invasive stage at diagnosis					
Stage I	2301 (63.4)	2030 (62.7)	4331 (63.1)	1.00 (reference)	
Stage II	1135 (31.2)	1018 (31.5)	2153 (31.3)	1.03 (0.92–1.14)	0.6375
Stage III	195 (5.4)	189 (5.8)	384 (5.6)	1.02 (0.82–1.26)	0.8898
Missing	276	170	446	–	
Invasive tumour size					
⩽0.5 cm (T1mic, T1a)	345 (9.5)	279 (9.0)	624 (9.3)	1.00 (reference)	
>0.5–⩽1.0 (T1b)	853 (23.6)	782 (25.2)	1635 (24.3)	1.11 (0.92–1.34)	0.2862
>1.0–⩽2.0 (T1c)	1538 (42.5)	1295 (41.7)	2833 (42.2)	1.01 (0.85–1.21)	0.9076
>2.0 (T2, T3, T4)	879 (24.3)	748 (24.1)	1627 (24.2)	1.02 (0.84–1.23)	0.8795
Missing	292	303	595		
Invasive nodal status					
Negative	2682 (76.3)	2404 (75.2)	5086 (75.8)	1.00 (reference)	
Positive	835 (23.7)	791 (24.8)	1626 (24.2)	1.05 (0.94–1.18)	0.3938
Missing	390	212	602		

Abbreviations: CI = confidence interval; DCIS = ductal carcinoma *in situ*; FNA = fine-needle aspiration; OR = odds ratio.
[a]Adjusted by year of screen, age at screening, screen type (initial *vs* rescreen), mammography type (film *vs* digital), mammographic density, income quintile, and community status.

consultation only at their first assessment visit. Women diagnosed at a BAC were two times more likely to have a core or FNA biopsy than a surgical biopsy (OR = 2.08, 95% CI = 1.81–2.40), and almost twice as likely to receive a diagnosis within 7 weeks of their abnormal mammogram (*vs* >7 weeks; OR = 1.91, 95% CI = 1.73–2.10) compared with those in UC. Sensitivity analyses on a subset of the cohort screened between 2006 and 2009 found similar results (Supplementary Table 1). Prognostic characteristics did not significantly differ between pathways.

Irrespective of pathway, women with breast cancer were more likely to be diagnosed within 7 weeks if they had their first procedure within 3 weeks, ⩾2 assessment procedures per visit, a biopsy during their first assessment visit compared with a consultation only, and a core/FNA compared with surgical biopsy at any visit (Table 3). In addition, women having an invasive breast cancer *vs* DCIS, stage II or III *vs* stage I, a larger tumour size (>0.5 *vs* ⩽0.5 cm), and positive *vs* negative nodal status were more likely to be diagnosed within 7 weeks, regardless of pathway. More advanced stage and larger tumour size increased the odds of being diagnosed within 7 weeks (test for trend $P < 0.0001$). Rurality decreased the likelihood of receiving a diagnosis within 7 weeks for both BAC and UC. Income quintile did not affect time to diagnosis in a BAC; however, women

Table 3. Adjusted ORs and 95% CIs for the association of breast cancer risk factors, screening, assessment, and prognostic characteristics by time to diagnosis (⩽7 vs >7 weeks) among women diagnosed with screen-detected breast cancers through a Breast Assessment Centre and Usual Care

Characteristic	Breast Assessment Centre (n = 4217)			Usual Care (n = 4827)		
	>7 Weeks, N = 1004, n (%)	⩽7 Weeks, N = 3213, n (%)	Adjusted OR (95% CI)	>7 Weeks, N = 1776, n (%)	⩽7 Weeks, N = 3051, n (%)	Adjusted OR (95% CI)
Screen type[a]						
Initial	289 (28.8)	941 (29.3)	1.00 (reference)	673 (37.9)	1186 (38.9)	1.00 (reference)
Rescreen	715 (71.2)	2272 (70.7)	0.97 (0.82–1.15)	1103 (62.1)	1865 (61.1)	0.96 (0.85–1.09)
Mammography type[a]						
Screen film	782 (77.9)	2543 (79.1)	1.00 (reference)	1604 (90.3)	2711 (88.9)	1.00 (reference)
Digital	222 (22.1)	670 (20.9)	1.12 (0.92–1.36)	172 (9.7)	340 (11.1)	1.12 (0.91–1.38)
Mammographic density[a]						
<75%	915 (91.1)	2991 (93.1)	1.00 (reference)	1600 (90.1)	2771 (90.8)	1.00 (reference)
⩾75%	89 (8.9)	222 (6.9)	0.78 (0.60–1.01)	176 (9.9)	280 (9.2)	0.91 (0.74–1.11)
Community status[a]						
Urban	756 (75.3)	2721 (84.7)	1.00 (reference)	1500 (84.5)	2617 (85.8)	1.00 (reference)
Rural	58 (5.8)	156 (4.9)	0.75 (0.55–1.03)	93 (5.2)	204 (6.7)	1.27 (0.98–1.63)
Rural remote	128 (12.7)	278 (8.7)	0.60 (0.48–0.75)[d]	102 (5.8)	132 (4.3)	0.75 (0.58–0.98)[e]
Rural very remote	62 (6.2)	57 (1.8)	0.26 (0.18–0.37)[d]	80 (4.5)	97 (3.2)	0.70 (0.52–0.95)[f]
Missing	0	1	–	1	1	–
Income quintile[a]						
1, Lowest	176 (17.6)	559 (17.5)	1.00 (reference)	309 (17.5)	462 (15.2)	1.00 (reference)
2	235 (23.6)	607 (19.0)	0.83 (0.66–1.04)	330 (18.7)	582 (19.2)	1.18 (0.97–1.44)
3	169 (17.0)	635 (19.8)	1.19 (0.94–1.52)	361 (20.5)	573 (18.9)	1.06 (0.87–1.29)
4	195 (19.6)	653 (20.4)	1.07 (0.84–1.35)	347 (19.7)	641 (21.1)	1.23 (1.01–1.49)[g]
5, Highest	222 (22.3)	748 (23.4)	1.07 (0.85–1.34)	418 (23.7)	777 (25.6)	1.24 (1.03–1.50)[h]
Missing	7	11	–	11	16	–
Time to first assessment procedure[b]						
>3 Weeks	387 (38.5)	407 (12.7)	1.00 (reference)	706 (39.8)	350 (11.5)	1.00 (reference)
⩽3 Weeks	617 (61.5)	2806 (87.3)	4.18 (3.53–4.94)[d]	1070 (60.3)	2701 (88.5)	5.12 (4.41–5.93)[d]
Total assessment procedures[b]						
>3 Procedures	595 (59.3)	741 (23.1)	1.00 (reference)	1039 (58.5)	995 (32.6)	1.00 (reference)
⩽3 Procedures	409 (40.7)	2472 (76.9)	4.97 (4.26–5.79)[d]	737 (41.5)	2056 (67.4)	2.95 (2.61–3.33)[d]
Total assessment visits[b]						
>2 Visits	632 (62.9)	457 (14.2)	1.00 (reference)	1098 (61.8)	820 (26.9)	1.00 (reference)
⩽2 Visits	372 (37.1)	2756 (85.8)	10.58 (8.96–12.50)[d]	678 (38.2)	2231 (73.1)	4.47 (3.94–5.07)[d]
Average number of procedures per visit[b]						
<2 Procedures per visit	883 (88.0)	2012 (62.6)	1.00 (reference)	1546 (87.1)	2071 (6.9)	1.00 (reference)
⩾2 Procedures per visit	121 (12.1)	1201 (37.4)	4.31 (3.51–5.29)[d]	230 (13.0)	980 (32.1)	3.18 (2.71–3.73)[d]
Procedure(s) at first visit[b]						
Consultation only	17 (1.7)	37 (1.2)	1.00 (reference)	57 (3.2)	91 (3.0)	1.00 (reference)
Imaging (± consultation)	917 (91.3)	2212 (68.8)	1.12 (0.62–2.02)	1651 (93.0)	2293 (75.2)	0.84 (0.60–1.18)
Biopsy (± imaging or consultation)	70 (7.0)	964 (30.0)	6.00 (3.18–11.33)[d]	68 (3.8)	667 (21.9)	6.05 (3.99–9.18)[d]
First biopsy procedure (any visit)[b]						
Open/surgical	150 (14.9)	196 (6.1)	1.00 (reference)	429 (24.2)	358 (11.7)	1.00 (reference)
Core/FNA	854 (85.1)	3016 (93.9)	2.85 (2.25–3.61)[d]	1346 (75.8)	2692 (88.3)	2.43 (2.06–2.86)[d]
Missing	0	1	–	1	1	–
Age at diagnosis (years)[c]						
50–59	475 (47.3)	1550 (48.2)	1.00 (reference)	833 (46.9)	1466 (48.0)	1.00 (reference)
60–70	529 (52.7)	1663 (51.8)	0.98 (0.85–1.13)	943 (53.1)	1585 (52.0)	0.95 (0.85–1.07)
Breast cancer classification[b]						
DCIS	305 (30.4)	505 (15.7)	1.00 (reference)	482 (27.1)	438 (14.4)	1.00 (reference)
Invasive	699 (69.6)	2708 (84.3)	2.41 (2.03–2.85)[d]	1294 (72.9)	2613 (85.6)	2.26 (1.95–2.62)[d]
Invasive stage at diagnosis[b]						
Stage I	451 (70.8)	1579 (60.7)	1.00 (reference)	836 (70.7)	1465 (59.8)	1.00 (reference)
Stage II	158 (24.8)	860 (33.1)	1.58 (1.29–1.93)[d]	307 (26.0)	828 (33.8)	1.55 (1.32–1.81)[d]
Stage III	28 (4.4)	161 (6.2)	1.82 (1.19–2.79)[i]	40 (3.4)	155 (6.3)	2.14 (1.49–3.08)[d]
Missing	62	108	–	111	165	–

Table 3. (Continued)

Characteristic	Breast Assessment Centre (n = 4217)			Usual Care (n = 4827)		
	>7 Weeks, N = 1004, n (%)	≤7 Weeks, N = 3213, n (%)	Adjusted OR (95% CI)	>7 Weeks, N = 1776, n (%)	≤7 Weeks, N = 3051, n (%)	Adjusted OR (95% CI)
Invasive tumour size[b]						
≤0.5 cm (T1mic, T1a)	87 (14.2)	192 (7.7)	1.00 (reference)	167 (14.0)	178 (7.3)	1.00 (reference)
>0.5–≤1.0 (T1b)	190 (31.1)	592 (23.8)	1.47 (1.09–2.00)[j]	347 (29.1)	506 (20.9)	1.36 (1.06–1.75)[k]
>1.0–≤2.0 (T1c)	235 (38.5)	1060 (42.5)	2.17 (1.62–2.91)[d]	460 (38.6)	1078 (44.5)	2.19 (1.73–2.79)[d]
>2.0 (T2, T3, T4)	99 (16.2)	649 (26.0)	3.18 (2.28–4.45)[d]	217 (18.2)	662 (27.3)	2.84 (2.18–3.69)[d]
Missing	88	215	–	103	189	–
Invasive nodal status[b]						
Negative	502 (79.2)	1902 (74.3)	1.00 (reference)	930 (81.7)	1752 (73.7)	1.00 (reference)
Positive	132 (20.8)	659 (25.7)	1.38 (1.11–1.71)[l]	209 (18.3)	626 (26.3)	1.59 (1.33–1.89)[d]
Missing	65	147	–	155	235	–

Abbreviations: CI = confidence interval; DCIS = ductal carcinoma *in situ*; FNA = fine-needle aspiration; OR = odds ratio.
[a] Adjusted by year of screen and age at screening.
[b] Adjusted by year of screen, age at screening, income quintile, and community status.
[c] Adjusted by year of screen, income quintile, and community status.
[d] $P < 0.0001$; [e] $P = 0.0362$; [f] $P = 0.0211$; [g] $P = 0.0386$; [h] $P = 0.0231$; [i] $P = 0.0058$; [j] $P = 0.0131$; [k] $P = 0.0175$; [l] $P = 0.0105$.


Figure 2. Distributions of time to diagnosis (in days) for women diagnosed through Breast Assessment Centres and Usual Care.

in the two highest quintiles (*vs* the lowest) were more likely to receive a diagnosis in 7 weeks (*vs* >7) when assessed through UC. Having ≤2 assessment visits was more likely to reduce time to diagnosis for women assessed through a BAC (OR = 10.58, 95% CI = 8.96–12.50) compared with UC (OR = 4.47, 95% CI = 3.94–5.07), as was having ≤3 assessment procedures (*vs* >3) (BAC OR = 4.97, 95% CI = 4.26–5.79; UC OR = 2.95, 95% CI = 2.61–3.73) (Table 3). Sensitivity analyses on a subset of the cohort screened between 2006 and 2009 found similar results (Supplementary Table 2).

Overall median wait times from abnormal screen to diagnosis were 28 days for women assessed through BACs and 39 days for UC (*P* < 0.0001; Figure 2). For women with ≤3 assessment procedures, the median time to diagnosis was 9 days shorter in a BAC compared with UC (BAC: 23 median days IQR = 15–39; UC: 32 median days IQR = 18–51; *P* < 0.0001) (Figure 3). Among women with >3 procedures, this difference still persisted (BAC: 45 median days IQR = 26–75; UC: 50 median days IQR = 34–79; *P* < 0.0001).

DISCUSSION

This study found that women with breast cancer were almost two times more likely to be diagnosed within 7 weeks when assessed

through a BAC *vs* UC. Irrespective of assessment pathway, women were significantly more likely to be diagnosed within 7 weeks if they had their first assessment procedure within 3 weeks (*vs* >3 weeks), ≥2 procedures per visit (*vs* <2), a biopsy at first visit compared with consultation only, and a core/FNA compared with open biopsy at any visit. Having ≤2 assessment visits and ≤3 assessment procedures was more likely to reduce time to diagnosis for women assessed through a BAC compared with UC. However, diagnostic wait time was significantly shorter in a BAC, regardless of the number of procedures.

Another Ontario study found that women undergoing organised assessment had 1.7 times greater odds of receiving a diagnosis within 7 weeks (Jiang *et al*, 2015), a result very similar to this study. Although the previous study included only 1 year of data, a large proportion of opportunistic screens, and only invasive cancers, this study and ours suggests that organised assessment is beneficial to women. Shorter diagnostic intervals were also seen among women with screen-detected breast cancer in Manitoba who received diagnostic work up through direct referral compared with UC (Decker *et al*, 2004). Women in British Columbia's direct referral program, "Fast Track", experienced similar improvement (Borugian *et al*, 2008), as did those receiving patient navigation in Nova Scotia (Psooy *et al*, 2004). Given our study, and others (Olivotto *et al*, 2001b; Decker *et al*, 2004; Psooy *et al*, 2004; Borugian *et al*, 2008; Baliski *et al*, 2014; Jiang *et al*, 2015), it appears that patient navigation and coordinated referral results in equitable expedited access to services, having a consistent benefit over UC.

Having ≤2 assessment visits and ≤3 assessment procedures was more likely to reduce time to diagnosis for women assessed through a BAC *vs* UC. For women with ≤3 assessment procedures, this difference could not be explained by time to first assessment procedure, which was similar between pathways. However, those in a BAC did have more procedures per visit than UC, resulting in more efficient visits. Women assessed through BACs also had assessment procedures scheduled in shorter intervals. In addition, type of procedure is important in shortening diagnostic wait times, as women assessed through BAC were more likely to have imaging or biopsy on their first assessment visit.

We found that open biopsy was uncommon overall, possibly because of the recommendation that tissue diagnosis of breast abnormalities be obtained before surgery (McCready *et al*, 2005; Bevers *et al*, 2009). Irrespective of pathway, those who underwent open biopsy were more likely to experience longer wait times to diagnosis than those having percutaneous FNA or core biopsy.

Figure 3. Median time and 90th percentile (in days) from abnormal mammogram to diagnosis for women diagnosed with screen-detected breast cancers, stratified by assessment centre type and number of assessment procedures ($\leqslant 3$ assessments (top) vs > 3 assessments (bottom)). Sample size within the assessment boxes represent the proportion of women who have had that assessment (i.e., who have not yet obtained a diagnosis).
[a]Wilcoxon rank-sum test for differences in median days to diagnosis (23 days vs 31 days) for $\leqslant 3$ assessment procedures, $p < 0.0001$.
[b]Wilcoxon rank-sum test for differences in median days to diagnosis (45 days vs 50 days) for > 3 assessment procedures, $p < 0.0001$.

This finding is consistent with research conducted in British Columbia (Olivotto *et al*, 2000) and across screening programs in Canada, including Ontario (Olivotto *et al*, 2001a). Wait times for operating rooms and the need for surgical consultations may be the most likely explanation for the delay. Recent findings have shown that women in rural areas have higher rates of open biopsy at diagnosis (Holloway *et al*, 2007). Although women attending BACs were more likely to live in rural areas, they had a lower proportion of open biopsies as a result of the standardisation of care pathways and improving access to guideline-based care. This in turn is likely to influence time to diagnosis (Olivotto *et al*, 2000,2001a). In addition, although those in UC were more likely to be diagnosed within 7 weeks if they were of higher income, income had no effect for women assessed within a BAC. This result might indicate an important benefit of organised assessment on social disparities.

Irrespective of pathway, women with invasive breast cancers of more advanced stage and larger tumour size were more likely to be diagnosed within 7 weeks as compared with those diagnosed at earlier stages with smaller tumours. This finding is consistent with literature demonstrating an expedited evaluation process for more overtly worrisome cases, where suspicious (Caplan *et al*, 2000; Olivotto *et al*, 2002; Ganry *et al*, 2004) and larger tumours (Bairati *et al*, 2007) were associated with decreased likelihood of diagnostic delay, and smaller tumours associated with increased delay (Molinié *et al*, 2013). Our results also align with research showing that women with less advanced stage were more likely to experience diagnostic delay compared with those with more advanced stage (Jiang *et al*, 2015), although their population also included symptomatic breast cancers.

Overall, women assessed through a BAC had more timely diagnoses and received fewer, more appropriate procedures. However, there are important considerations to facilitate the

establishment of organised breast assessment centres. In Ontario, BACs require additional practitioners, access to diagnostic specialists, and adequate imaging, biopsy, and pathological assessment capacity (Quan *et al*, 2012; Jiang *et al*, 2015). These requirements may be more challenging in remote settings, in addition to being more costly.

The strengths of this study include its use of existing data collected on a large population-based cohort of screened women during an 8-year period. All eligible women were identified from a centralised screening database, and follow-up was identical. Women diagnosed through BACs were similar to women diagnosed through UC by age at screen and at diagnosis and on breast cancer risk factors and prognostic characteristics. However, the two cohorts did differ significantly by year of screen and region of screening centre as this would reflect when and where the BACs were implemented. To ensure comparability, any differences in year of screen, screen type, mammography type, mammographic density, income quintile, and community status were adjusted for in analyses.

There were several limitations to the study. First, it was not possible to distinguish between system-level and certain patient-level factors associated with diagnostic delay. Patient-level factors that can influence diagnostic times include poorer health (Yabroff *et al*, 2004), patient beliefs and attitudes (Yabroff *et al*, 2004; Allen *et al*, 2008), and logistical barriers to accessing services (Allen *et al*, 2008). However, recent reviews have not been able to estimate the proportion of diagnostic delay that might be due to patient *vs* system-level factors (Wujcik and Fair, 2008; Zapka *et al*, 2010). In addition, compared with UC, a greater proportion of women in the BAC cohort were seen in a more recent time period, when percutaneous biopsy has become standardised and more accessible. Lastly, this study focussed solely on patients with cancer diagnoses.

We are not able to determine how diagnostic wait times would compare for patients with a benign outcome who often undergo less prompt assessment than those with overtly suspicious findings.

The benefits of early detection by mammography are dependent on women with abnormal screening results having access to timely and accurate diagnostic assessment. This study examined the impact of procedures and visits on diagnostic delays and found that women with screen-detected breast cancer in OBSP were more likely to have shorter wait times if they were seen through organised assessment. This was likely because of fewer, timelier, more appropriate assessment procedures for women diagnosed through BACs vs UC. Given the significant improvement in timeliness to diagnosis, women with abnormal mammograms should be managed through organised assessment. Future work will address the impact of diagnostic and treatment intervals on breast cancer survival by assessment pathway.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Allen JD, Shelton RC, Harden E, Goldman RE (2008) Follow-up of abnormal screening mammograms among low-income ethnically diverse women: findings from a qualitative study. *Patient Educ Couns* 72: 283–292.

American Joint Committee on Cancer (2002) *Cancer Staging Manual*, 6th edn. Springer-Verlag: New York.

Bairati I, Jobin E, Fillion L, Larochelle M, Vincent L (2007) Determinants of delay for breast cancer diagnosis. *Cancer Detect Prev* 31: 323–331.

Baliski C, Mcgahan CE, Liberto CM, Broughton S, Ellard S, Taylor M, Bates J, Lai A (2014) Influence of nurse navigation on wait times for breast cancer care in a Canadian regional cancer center. *Am J Surg* 207: 686–692.

Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yankeelov T, National Comprehensive Cancer Network (2009) NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. *J Natl Compr Canc Netw* 7: 1060–1096.

Borugian MJ, Kan L, Chu CC, Ceballos K, Gelmon KA, Gordon PB, Poole B, Tyldesley S, Olivotto IA (2008) Facilitated "Fast Track" referral reduces time from abnormal screening mammogram to diagnosis. *Can J Public Health* 99: 252–256.

Brett J, Austoker J, Ong G (1998) Do women who undergo further investigation for breast screening suffer adverse psychological consequences? A multi-centre follow-up study comparing different breast screening result groups five months after their last breast screening appointment. *J Public Health Med* 20: 396–403.

Canadian Breast Cancer Screening Initiative Working Group (2000) *Canadian Breast Cancer Screening Initiative Working Group on the Integration of Screening and Diagnosis: Waiting for a diagnosis after an abnormal breast cancer screen in Canada*. Minister of Public Works and Government Services: Ottawa.

Canadian Partnership against Cancer (2013) *Report from the Evaluation Indicators Working Group: Guidelines for Monitoring Breast Cancer Screening Program Performance*. 3rd edn, Canadian Partnership Against Cancer Toronto.

Caplan LS, May DS, Richardson LC (2000) Time to diagnosis and treatment of breast cancer: results from the National Breast and Cervical Cancer Early Detection Program, 1991–1995. *Am J Public Health* 90: 130–134.

Chiarelli AM, Edwards SA, Prummel MV, Muradali D, Majpruz V, Done SJ, Brown P, Shumak RS, Yaffe MJ (2013) Digital compared with screen-film mammography: performance measures in concurrent cohorts within an organized breast screening program. *Radiology* 268: 684–693.

Decker KM, Harrison M, Chateau D (2004) Influence of direct referrals on time to diagnosis after an abnormal breast screening result. *Cancer Detect Prev* 28: 361–367.

Diggle PJ, Heagerty P, Liang K, Zeger SL (2002) *Analysis of Longitudinal Data*. Oxford University Press: Oxford.

Ganry O, Peng J, Dubreuil A (2004) Influence of abnormal screens on delays and prognostic indicators of screen-detected breast carcinoma. *J Med Screen* 11: 28–31.

Haynes W (2013) *Wilcoxon Rank Sum Test. Encyclopedia of Systems Biology*. Springer: New York, NY, USA.

Holloway CM, Saskin R, Brackstone M, Paszat L (2007) Variation in the use of percutaneous biopsy for diagnosis of breast abnormalities in Ontario. *Ann Surg Oncol* 14: 2932–2939.

Jaro MA (1995) Probabilistic linkage of large public health data files. *Stat Med* 14: 491–498.

Jiang L, Gilbert J, Langley H, Moineddin R, Groome P (2015) Effect of specialized diagnostic assessment units on the time to diagnosis in screen-detected breast cancer patients. *Br J Cancer* 112: 1744–1750.

McCready D, Holloway C, Shelley W, Down N, Robinson P, Sinclair S, Mirsky D, Breast Cancer Disease Site Group of Cancer Care, Ontario's Program in Evidence-Based Care (2005) Surgical management of early stage invasive breast cancer: a practice guideline. *Can J Surg* 48: 185–194.

Molinié F, Leux C, Delafosse P, Ayrault-Piault S, Arveux P, Woronoff A, Guizard A, Velten M, Ganry O, Bara S (2013) Waiting time disparities in breast cancer diagnosis and treatment: a population-based study in France. *Breast* 22: 810–816.

Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L (2016) Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 US Preventive Services Task Force recommendation. *Ann Intern Med* 164: 244–255.

Olivotto IA, Bancej C, Goel V, Snider J, Mcauley RG, Irvine B, Kan L, Mirsky D, Sabine MJ, Mcgilly R, Caines JS (2001a) Waiting times from abnormal breast screen to diagnosis in 7 Canadian provinces. *CMAJ* 165: 277–283.

Olivotto IA, Borugian MJ, Kan L, Harris SR, Rousseau EJ, Thorne SE, Vestrup JA, Wright CJ, Coldman AJ, Hislop TG (2001b) Improving the time to diagnosis after an abnormal screening mammogram. *Can J Public Health* 92: 366–371.

Olivotto IA, Gomi A, Bancej C, Brisson J, Tonita J, Kan L, Mah Z, Harrison M, Shumak R (2002) Influence of delay to diagnosis on prognostic indicators of screen-detected breast carcinoma. *Cancer* 94: 2143–2150.

Olivotto IA, Kan L, King S (2000) Waiting for a diagnosis after an abnormal screening mammogram. *Can J Public Health* 91: 113–117.

Ontario Breast Screening Program (2001) *Multidisciplinary Roles and Expectations for Breast Assessment in Ontario*. The Breast Assessment Collaborative Group: Toronto.

Psooy BJ, Schreuer D, Borgaonkar J, Caines JS (2004) Patient navigation: improving timeliness in the diagnosis of breast abnormalities. *Can Assoc Radiol J* 55: 145–150.

Quan ML, Shumak RS, Majpruz V, Holloway CM, O'Malley FP, Chiarelli AM (2012) Improving work-up of the abnormal mammogram through organized assessment: Results from the ontario breast screening program. *J Oncol Pract* 8: 107–112.

Rimer BK, Bluman LG (1997) The psychosocial consequences of mammography. *J Natl Cancer Inst Monogr* 22: 131–138.

SAS Institute Inc (2008) Statistical Analysis Software. 9.4 edn. SAS Institute: Cary.

Statistics Canada (1997) *1996 Census dictionary. Report No.: 92-325-UIE*. Statistics Canada: Ottawa.

Sutton S, Saidi G, Bickler G, Hunter J (1995) Does routine screening for breast cancer raise anxiety? Results from a three wave prospective study in England. *J Epidemiol Community Health* 49: 413–418.

The Canadian Task Force on Preventive Health Care (2011) Recommendations on screening for breast cancer in average-risk women aged 40–74 years. *CMAJ* 183: 1991–2001.

The Workshop Group (1989) Reducing deaths from breast cancer in Canada. *Can Med Assoc J* **141**: 199–201.

Wilkins R (1998) *Geocodes/PCCF Version 3 User's Guide: Automated Geographic Coding based on the Statistics Canada Postal Code Conversion Files*. Health Statistics Division, Statistics Canada: Ottawa.

World Health Organization (1990) *International Classification of Diseases for Oncology (ICD-O)*. WHO: Geneva.

Wujcik D, Fair AM (2008) Barriers to diagnostic resolution after abnormal mammography: a review of the literature. *Cancer Nurs* **31**: E16–E30.

Yabroff KR, Breen N, Vernon SW, Meissner HI, Freedman AN, Ballard-Barbash R (2004) What factors are associated with diagnostic follow-up after abnormal mammograms? Findings from a US National Survey. *Cancer Epidemiol Biomarkers Prev* **13**: 723–732.

Zapka J, Taplin SH, Price RA, Cranos C, Yabroff R (2010) Factors in quality care–the case of follow-up to abnormal cancer screening tests– problems in the steps and interfaces of care. *J Natl Cancer Inst Monogr* **2010**: 58.

[1]*Prevention and Cancer Control, Cancer Care Ontario, 620 University Avenue, Toronto, Ontario M5G 2L7, Canada;* [2]*Dalla Lana School of Public Health, University of Toronto, 155 College Street, 6th floor, Toronto, Ontario M5T 3M7, Canada;* [3]*St Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada;* [4]*Department of Medical Imaging, University of Toronto, 263 McCaul Street, 4th Floor, Toronto, Ontario M5T 1W7, Canada;* [5]*Phoenix Children's Hospital, 1919 East Thomas Road, Phoenix, Arizona 85016, USA;* [6]*Department of Laboratory Medicine, St Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada;* [7]*Calgary Breast Health Program, Foothills Medical Centre, 1403–29 Street NW, Calgary, Alberta T2N 2T9, Canada;* [8]*Department of Surgery and Surgical Oncology, University of Calgary, 1331–29 Street NW, Calgary, Alberta T2N 4N2, Canada;* [9]*Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada and* [10]*Department of Surgery, University of Toronto, 149 College Street, 5th Floor, Toronto, Ontario M5T 1P5, Canada*

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)